JavaScript is NOT enabled !

Please enable JavaScript.

* Show help

Reset

MeSH: Mycotoxins Organization: CheckMate 77T Investigators

1 hits in Medvik Filters

Online article

Perioperative Nivolumab in Resectable Lung Cancer

Cascone, Tina
Author Cascone, Tina From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Awad, Mark M
Author Awad, Mark M From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Spicer, Jonathan D
Author Spicer, Jonathan D From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
He, Jie
Author He, Jie From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Lu, Shun
Author Lu, Shun From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Sepesi, Boris
Author Sepesi, Boris From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Tanaka, Fumihiro
Author Tanaka, Fumihiro From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Taube, Janis M
Author Taube, Janis M From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Cornelissen, Robin
Author Cornelissen, Robin ORCID From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)
Havel, Libor
Author Havel, Libor From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.) Dana-Farber Cancer Institute, Boston (M.M.A.) McGill University Health Centre, Montreal (J.D.S.) the National Cancer Center-National Clinical Research Center for Cancer-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.), Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (S.L.), and Hunan Cancer Hospital (L.W.) and Xiangya Hospital, Central South University (Y.G.), Changsha - all in China the University of Occupational and Environmental Health, Kitakyushu (F.T.), Kanagawa Cancer Center, Yokohama (H.I.), and Saitama Cancer Center, Saitama (Y.W.) - all in Japan Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (J.M.T.) Erasmus MC Cancer Institute, Rotterdam, the Netherlands (R.C.) Thomayer Hospital (L.H.) and Charles University (L.B.P.) - both in Prague, Czech Republic St. Petersburg State Budgetary Healthcare Institution, Clinical Oncology Dispensary (N.K.), and St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (F.V.M.) - both in St. Petersburg, Russia Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, Poland (J.K.) Montpellier Regional University Hospital, Montpellier, France (J.-L.P.) Prof. Dr. Ion Chiricuta and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca (T.-E.C.), and Institutul Oncologic București Prof. Dr. Alexandru Trestioreanu, Bucharest (A.A.) - both in Romania Hospital Israelita Albert Einstein, São Paulo (L.O.M.K.) Antwerp University Hospital, Edegem, Belgium (A.J.) Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (S.B.) Bristol Myers Squibb, Princeton, NJ (C.C.E., P.S., S.M.-S., S.I.B.) and Hospital Universitario Puerta de Hierro, Madrid (M.P.P.)

The New England journal of medicine. 2024 ; 390 (19) : 1756-1769. [pub] 20240516

N Engl J Med
ISSN 1533-4406
Medvik
Source

BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes. METHODS: In this phase 3, randomized, double-blind trial, we assigned adults with resectable stage IIA to IIIB NSCLC to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary outcome was event-free survival according to blinded independent review. Secondary outcomes were pathological complete response and major pathological response according to blinded independent review, overall survival, and safety. RESULTS: At this prespecified interim analysis (median follow-up, 25.4 months), the percentage of patients with 18-month event-free survival was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (hazard ratio for disease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% confidence interval [CI], 0.42 to 0.81; P<0.001). A pathological complete response occurred in 25.3% of the patients in the nivolumab group and in 4.7% of those in the chemotherapy group (odds ratio, 6.64; 95% CI, 3.40 to 12.97); a major pathological response occurred in 35.4% and 12.1%, respectively (odds ratio, 4.01; 95% CI, 2.48 to 6.49). Grade 3 or 4 treatment-related adverse events occurred in 32.5% of the patients in the nivolumab group and in 25.2% of those in the chemotherapy group. CONCLUSIONS: Perioperative treatment with nivolumab resulted in significantly longer event-free survival than chemotherapy in patients with resectable NSCLC. No new safety signals were observed. (Funded by Bristol Myers Squibb; CheckMate 77T ClinicalTrials.gov number, NCT04025879.).

Collections

Published

Filters

* Show help

* Show help

Refine by MeSH